低氧誘導(dǎo)因子脯氨酰羥化酶抑制劑治療腎性貧血的研究進展
發(fā)布時間：2018-07-29 11:41
【摘要】：慢性腎臟病(chronic kidney disease,CKD)是一種長期性進展性疾病,是以腎功能丟失逐漸加重為特征的一種疾病,甚至?xí)䦟?dǎo)致終末期腎臟疾病,需要腎移植或者腎透析。貧血是CKD患者的常見并發(fā)癥,且隨腎功能下降貧血發(fā)生率不斷上升。紅細胞生成刺激劑(erythropoiesis stimulating agents,ESAs)是目前治療腎性貧血的主導(dǎo)藥物,然而,心血管安全風(fēng)險限制了ESAs的應(yīng)用。所以,近幾年開始探索新型的紅細胞生成刺激劑制劑,一種新型口服的低氧誘導(dǎo)因子脯氨酰羥化酶(hypoxia-inducible factor-prolyl hydroxylase,HIF-PHD)抑制劑,日益受到國內(nèi)外研究人員的關(guān)注,然而系統(tǒng)的綜述較少。鑒于此,本文將對新型的口服低氧誘導(dǎo)因子脯氨酰羥化酶抑制劑的作用機制及全球研究進展進行綜述,重點對目前研發(fā)比較成熟進入臨床階段的藥物進行綜述。
[Abstract]:Chronic kidney disease (chronic kidney) is a long-term progressive disease characterized by gradual deterioration of renal function. It may even lead to end-stage renal disease requiring kidney transplantation or renal dialysis. Anemia is a common complication in patients with CKD, and the incidence of anemia increases with the decline of renal function. ESAs, a erythrocyte stimulating agent, is the leading drug in the treatment of renal anemia. However, cardiovascular safety risks limit the use of ESAs. Therefore, in recent years, researchers at home and abroad have been paying more and more attention to a new erythrocyte stimulating agent, a new type of hypoxia-inducible factor-prolyl hydroxylase HIF-PhD inhibitor, which has been systematically reviewed. In view of this, this article will review the action mechanism and global research progress of new oral hypoxia inducible factor proline hydroxylase inhibitors, focusing on the current research and development of more mature drugs into the clinical stage.
【作者單位】： 江蘇德源藥業(yè)股份有限公司;
【分類號】：R969.4
本文編號：2152569
[Abstract]:Chronic kidney disease (chronic kidney) is a long-term progressive disease characterized by gradual deterioration of renal function. It may even lead to end-stage renal disease requiring kidney transplantation or renal dialysis. Anemia is a common complication in patients with CKD, and the incidence of anemia increases with the decline of renal function. ESAs, a erythrocyte stimulating agent, is the leading drug in the treatment of renal anemia. However, cardiovascular safety risks limit the use of ESAs. Therefore, in recent years, researchers at home and abroad have been paying more and more attention to a new erythrocyte stimulating agent, a new type of hypoxia-inducible factor-prolyl hydroxylase HIF-PhD inhibitor, which has been systematically reviewed. In view of this, this article will review the action mechanism and global research progress of new oral hypoxia inducible factor proline hydroxylase inhibitors, focusing on the current research and development of more mature drugs into the clinical stage.
【作者單位】： 江蘇德源藥業(yè)股份有限公司;
【分類號】：R969.4
【相似文獻】
相關(guān)期刊論文 前2條
1 孟慶林;樸翔宇;;低氧誘導(dǎo)因子抑制藥在抗腫瘤方面的研究進展[J];醫(yī)藥導(dǎo)報;2013年07期
2 牛非;李燕;來芳芳;陳曉光;;低氧誘導(dǎo)因子1抑制劑的抗腫瘤研究進展[J];藥學(xué)學(xué)報;2014年06期
相關(guān)會議論文 前3條
1 趙建;張連方;陳博;齊進;周琦;王晉申;錢念東;鄧廉夫;;局部應(yīng)用低氧誘導(dǎo)因子激活劑對去勢小鼠骨折愈合的促進作用[A];第十八屆全國中西醫(yī)結(jié)合骨傷科學(xué)術(shù)研討會論文匯編[C];2011年
2 關(guān)雅瓊;盛榮;胡永洲;;低氧誘導(dǎo)因子HIF-1α抑制劑研究進展[A];2012長三角藥物化學(xué)研討會論文集[C];2012年
3 鄒穎;王斌;倪永兵;肖繼皋;張愛霞;王鵑;;低氧誘導(dǎo)因子1在PC12細胞化學(xué)缺氧復(fù)氧損傷中的作用[A];中國藥理學(xué)會第八次全國代表大會暨全國藥理學(xué)術(shù)會議論文摘要匯編[C];2002年
，本文編號：2152569
本文鏈接：http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2152569.html
最近更新
教材專著
